/PSTV
PSTV Stock - Plus Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.57+3.08%
+$0.02 (+3.08%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+251.8%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PSTV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.56 – $0.57
TARGET (TP)$2.00
STOP LOSS$0.52
RISK/REWARD1:29.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.82
52W High$2.31
52W Low$0.16
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.82M | $4.91M | $224,000 | N/A | $303,000 |
| Gross Profit | $4.97M | $-4,777,000 | $-488,000 | $-66,000 | $-2,397,000 |
| Gross Margin | 85.4% | -97.2% | -217.9% | N/A | -791.1% |
| Operating Income | $-14,695,000 | $-13,321,000 | $-19,712,000 | $-12,492,000 | $-9,584,000 |
| Net Income | $-12,978,000 | $-13,316,000 | $-20,275,000 | $-13,399,000 | $-8,241,000 |
| Net Margin | -222.8% | -271.0% | -9051.3% | N/A | -2719.8% |
| EPS | $-1.95 | $-4.24 | $-11.55 | $-17.78 | $-27.90 |
Company Overview
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$7
Average Target
↑ 1131.3% Upside
Now
$5
Low
$7
Average
$9
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 3rd 2025 | D. Boral Capital | Upgrade | Buy | $5 |
| March 17th 2025 | D. Boral Capital | Initiation | Buy | $9 |
Earnings History & Surprises
PSTVBeat Rate
26%
Last 19 quarters
Avg Surprise
-19.8%
EPS vs Estimate
Beats / Misses
5/12
2 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
+10.3%
$-0.70vs$-0.78
Q2 24
+31.2%
$-0.75vs$-1.09
Q3 24
-34.0%
$-0.71vs$-0.53
Q4 24
0.0%
$-0.46vs$-0.46
Q1 25
-31.4%
$-0.67vs$-0.51
Q2 25
-229.4%
$-0.56vs$-0.17
Q3 25
+88.9%
$-0.01vs$-0.09
Q4 25
-100.0%
$-0.04vs$-0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.03 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.02 | $-0.04 | -100.0% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.09 | $-0.01 | +88.9% | ✓ BEAT |
Q2 2025 | May 30, 2025 | $-0.17 | $-0.56 | -229.4% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.51 | $-0.67 | -31.4% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.46 | $-0.46 | 0.0% | = MET |
Q3 2024 | Aug 14, 2024 | $-0.53 | $-0.71 | -34.0% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-1.09 | $-0.75 | +31.2% | ✓ BEAT |
Q1 2024 | Mar 5, 2024 | $-0.78 | $-0.70 | +10.3% | ✓ BEAT |
Q4 2023 | Oct 31, 2023 | $-0.58 | $-1.00 | -72.4% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-1.91 | $-0.59 | +69.1% | ✓ BEAT |
Q2 2023 | Apr 20, 2023 | $-2.10 | $-2.10 | 0.0% | = MET |
Q1 2023 | Feb 23, 2023 | $-2.25 | $-2.40 | -6.7% | ✗ MISS |
Q4 2022 | Oct 20, 2022 | $-3.15 | $-2.85 | +9.5% | ✓ BEAT |
Q3 2022 | Jul 21, 2022 | $-2.70 | $-3.60 | -33.3% | ✗ MISS |
Q2 2022 | Apr 21, 2022 | $-2.55 | $-2.85 | -11.8% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-3.45 | $-4.05 | -17.4% | ✗ MISS |
Q4 2021 | Oct 21, 2021 | $-3.15 | $-4.20 | -33.3% | ✗ MISS |
Q3 2021 | Jul 22, 2021 | $-3.45 | $-3.75 | -8.7% | ✗ MISS |
Q2 2021 | Apr 22, 2021 | $-4.65 | $-4.95 | -6.5% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Dec 11, 2025, 06:35 PM
Plus Therapeutics Unit Expands Reach as CNSide Cancer Test Nears Nationwide Availability
📈 PositiveBenzinga•Dec 11, 2025, 12:34 PM
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Dec 1, 2025, 06:25 PM
Plus Therapeutics To Present ReSPECT Phase 1 Dose Escalation Study Results For Leptomeningeal Metastases At 2025 SABCS
📈 PositiveBenzinga•Dec 1, 2025, 12:38 PM
Plus Therapeutics Completes Type B Meeting With FDA On November 7th To Discuss REYOBIQ Clinical Development Plans For LM Including Design Of Planned Pivotal Or Registrational Trial
➖ NeutralBenzinga•Nov 24, 2025, 12:31 PM
Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $19
➖ NeutralBenzinga•Nov 21, 2025, 10:46 AM
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Nov 20, 2025, 02:28 PM
Plus Therapeutics' CNSide Diagnostics Signs National Agreement With Humana To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Laboratory Developed Test
📈 PositiveBenzinga•Nov 20, 2025, 12:34 PM•Also:
Plus Therapeutics Receives Additional 180-Day Extension Period From Nasdaq To Regain Compliance
➖ NeutralBenzinga•Nov 17, 2025, 12:33 PM
Plus Therapeutics To Present REYOBIQ And ReSPECT-LM Clinical Data On Leptomeningeal Metastases At SITC And MRF Brain Metastases Summit
📈 PositiveBenzinga•Nov 6, 2025, 12:40 PM
HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $2
➖ NeutralBenzinga•Nov 3, 2025, 11:31 AM
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Oct 31, 2025, 11:51 AM
Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
📉 NegativeBenzinga•Oct 30, 2025, 08:28 PM
PLUS THERAPEUTICS shares are trading higher after the company announced it expanded its commercial readiness and diagnostic manufacturing footprints and secured a coverage deal with UnitedHealthcare.
📈 PositiveBenzinga•Oct 21, 2025, 01:23 PM•Also:
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Oct 21, 2025, 12:28 PM
Plus Therapeutics Expands CNSide Diagnostic Business, Lands National Coverage Deal With UnitedHealthcare
📈 PositiveBenzinga•Oct 21, 2025, 11:42 AM•Also:
Plus Therapeutics shares are trading higher after Ascendiant Capital maintained a Buy rating on the stock and raised its price target from $20.5 to $21.
📈 PositiveBenzinga•Oct 6, 2025, 02:58 PM
Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $21
📈 PositiveBenzinga•Oct 6, 2025, 10:07 AM
Plus Therapeutics rises on the back of UnitedHealthcare coverage deal
📈 PositiveSeeking Alpha•Sep 25, 2025, 12:37 PM•Also:
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Sep 25, 2025, 12:14 PM
Frequently Asked Questions about PSTV
What is PSTV's current stock price?
Plus Therapeutics, Inc. (PSTV) is currently trading at $0.57 per share. The stock has moved +3.08% today.
What is the analyst price target for PSTV?
The average analyst price target for PSTV is $2.00, based on 1 analyst.
What sector is Plus Therapeutics, Inc. in?
Plus Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PSTV's market cap?
Plus Therapeutics, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does PSTV pay dividends?
No, Plus Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PLUR
Pluri Inc.
$3.40
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to PSTV for comparison